

Liver Fibrosis




CCl₄-Induced Mouse Model


Liver fibrosis occurs in most types of chronic liver diseases. To test the efficacy of new drugs against liver disease, mice can be systemically injected with carbon tetrachloride (CCl4). CCl4 is an organochloride and known as one of the most potent hepatotoxins and as such inducing liver fibrosis.

C57Bl/6 mice at an age of 7 weeks are intraperitoneally treated three times per week with CCl4 or vehicle for a total of 9 weeks to induce liver fibrosis.


- · Liver to body weight ratio
- Increased Col1a1 mRNA and protein levels
- · Increased Acta2 mRNA levels
- · Increased hydroxyproline protein levels
- Increased smooth muscle actin (SMA) protein levels


Figure 1:
Body weight and liver
to body weight ratio of
CCl4- and vehicle-treated
C57Bl/6JRccHsd mice.
A: body weight.
B: Liver to body weight
ration. Unpaired t-test.
n = 6 per group; mean +
SEM. ***p<0.001; n.s.: not
significant.








Expression levels of typical liver disease markers after CCl4 treatment. mRNA expression levels of Col1a1 (A) and Acta2 (B). Levels are presented as x- fold change using the 2^(-ΔΔCT) method in relation to the HKG HPRT and vehicle. C: Hydroxyproline protein levels in ng/µl. Quantification of Col1a1 **(D)** and SMA (**E**, smooth muscle actin) immunoreactive (IR) area in percent. A-E: All markers were measured in the liver after 9 weeks of CCl4 or vehicle treatment. Unpaired t-test; n = 5/6 per group; mean + SEM; *p<0.05, **p<0.01, ***p<0.001.











Scantox

Discovery

Important note

Representative data are shown throughout this document. However, biological variability might cause deviations from shown data.

Scantox Group, HQ

Hestehavevej 36A, Ejby DK – 4623 Lille Skensved clientservice@scantox.com www.scantox.com +45 5686 1500

© Scantox A/S

Scantox is a registered trademark of Scantox A/S.

